Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib

Overview of attention for article published in Cancer & Metabolism, May 2014

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 3,897 followers.

"http://t.co/m70kLM9tPw’s PFK-158 Selected as One of... http://t.co/ft1DXPYmpi" via @kymedicalnews. See http://t.co/daN8Pz5e2g.

Reply Repost Favourite

"http://t.co/m70kLM9tPw’s PFK-158 Selected as One of... http://t.co/ft1DXPYmpi" via @kymedicalnews. See http://t.co/daN8Pz5e2g.

Reply Repost Favourite

"http://t.co/YMhkCUqJVB’s PFK-158 Selected as One of... http://t.co/Q85QAYLVWm" via @kymedicalnews. See http://t.co/7bHdhEHJCV. @uofl

Reply Repost Favourite

"http://t.co/m70kLM9tPw’s PFK-158 Selected as One of... http://t.co/ft1DXPYmpi" via @kymedicalnews. See http://t.co/daN8Pz5e2g.

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.